Project Grant RF1NS148023
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $119,367 to the University of California, San Francisco on August 11, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to support investigative research into the RNA-related functions of tau protein in frontotemporal dementia (FTD). The two-year project, concluding July 31, 2027, focuses on characterizing how tau functions in...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $634,938 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2026, through May 31, 2031. The award supports fundamental and translational research investigating RNA editing dysregulation in Dementia with Lewy Bodies (DLB) and Parkinson's...
- Federal Project Grant Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3.11 million Project Grant to the University of California, Los Angeles (UCLA) Office of Research Administration, effective August 1, 2025 through July 31, 2029, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This grant supports the development and validation of human induced pluripotent stem cell (iPSC)-derived hippocampal...
- Federal Project Grant Award Summary The University of Illinois received a $1,592,854 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective June 1, 2025, through May 31, 2027. This award funds research investigating tau protein conformation in tauopathies, including Alzheimer's disease and related dementias such as progressive supranuclear palsy, cortical basal degeneration, and chronic traumatic encephalopathy. The research centers on...
- Federal Project Grant Award Summary Northwestern University received a $438,606 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 1, 2025 through July 31, 2027. The research project focuses on establishing induced pluripotent stem cell (iPSC)-based models to investigate the mechanistic interaction between neurotrauma and amyotrophic...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $148,614 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective February 15, 2026, with completion targeted for January 31, 2029. The award funds research investigating the clinical, anatomic, and pathologic progression of semantic language impairment in the Type C variant of frontotemporal lobar degeneration due to TDP-43 (TDP-C) pathology....
- Federal Grant Award Summary The University of Illinois received a $6.67 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with a completion date of August 31, 2029. This grant supports research to develop small molecule ligands targeting pathological tau signaling in Alzheimer's disease and related dementias. The research focuses on identifying drug candidates that block the tau phosphatase activating domain...
- Federal Grant Award Summary New York University received a $422,297 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded February 15, 2026, with a completion date of January 31, 2028. The award supports biomedical research investigating the mechanisms by which Frontotemporal Dementia (FTD)-associated tau mutations dysregulate protein synthesis in human neurons. The research utilizes human induced pluripotent stem cell (iPSC)-derived neurons carrying...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Project Grant Award Summary Novoron Bioscience Inc. received a $1,257,528 Project Grant from the National Institute on Aging (CFDA 93.866, Aging Research program) awarded on September 16, 2025, with a completion date of May 31, 2027. The awardee will develop and validate a platform using human induced pluripotent stem cell (hiPSC)-derived neural spheroids to screen for compounds that inhibit tau protein propagation and aggregation. The research addresses a critical need in Alzheimer's...
Northwestern University's Sponsored Research Division received a $1.84 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 15, 2026, with completion scheduled for March 31, 2029. The award funds preclinical research to develop a gene therapy targeting tauopathies—a group of neurodegenerative disorders including Frontotemporal Dementia (FTD), Alzheimer's Disease (AD), and Progressive Supranuclear Palsy (PSP)—that share a common pathologic feature of abnormal tau protein deposition in the brain. The research initiative will conduct in vivo and in vitro studies to validate the therapeutic potential of inhibiting Bone Morphogenetic Protein (BMP) signaling as a mechanism to reduce tau phosphorylation and disease progression. Products and deliverables include preclinical data from mouse models (P301S tauopathy and human APOE4 knockin models), human induced pluripotent stem cell (iPSC)-derived neuron analyses, and translational evidence supporting BMP inhibition—particularly through NOGGIN administration—as a viable intervention strategy to prevent tau hyperphosphorylation, neuropathological changes, and associated behavioral abnormalities in aging brain.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.8m | 5/11/26 |